Inhibitor in Medical Technology
Navigation Links
Inhibitor in Medical Technology
... to be a best-in-class nucleoside/tide polymerase inhibitor with demonstrated antiviral activity and ... coming months from our non-nucleoside polymerase inhibitor and protease inhibitor programs, we are closer to achieving our ultimate ...
... non-nucleoside reverse transcriptase inhibitor (NNRTI) TMC278 (rilpivirine hydrochloride 25 mg) ... with a non-nucleoside reverse transcriptase inhibitor or a protease inhibitor as a preferred regimen for patients initiating ...
... Medicine, Proteolix's selective immunoproteasome inhibitor PR-957 was shown to block disease progression in ... print edition in an article titled: A Selective inhibitor of the Immunoproteasome Subunit LMP7 Blocks ... is the first highly selective, small molecule inhibitor of the immunoproteasome. The proteasome is an ...
... activity as a highly selective and potent inhibitor of the proteasome for treatment of solid tumor ... for carfilzomib as a promising new protease inhibitor in hematologic and solid tumor malignancies. ... including a selective, oral proteasome inhibitor and a selective immunoproteasome inhibitor. For ...
... "We've known that these CYP2D6 inhibitor drugs block the activation of tamoxifen ... far lower levels in the blood stream when CYP2D6 inhibitor drugs are present, and it is the first study to ... that patients used tamoxifen and a CYP2D6 inhibitor concurrently was 340 days. The analysis ...
... Failing Treatment Either with a VEGF Receptor inhibitor or after Treatment with both a VEGF Receptor inhibitor and an mTOR inhibitor NEW YORK, May 29 /PRNewswire-FirstCall/ -- ...
... dimesylate) CII with the proton pump inhibitor (PPI) Prilosec OTC(R) 40 mg (20 mg X 2), did not ... the first to evaluate the impact of a proton pump inhibitor on the amphetamine pharmacokinetics of VYVANSE ... drugs; agitated states; taken a monoamine oxidase inhibitor (MAOI) within the last 14 days. Tell the ...
... for Semafore's vascular targeted pan-PI3K/mTOR inhibitor is scheduled as follows: Time: ... SF1126 a vascular targeted PI3K Title: inhibitor administered twice weekly IV in patients with ... only clinical stage vascular targeted pan-PI3K inhibitor that selectively inhibits all PI3K class I ...
... 2992 is an orally-administered, irreversible dual inhibitor of the epidermal growth factor receptor (EGFR) ... with a second-line or third-line reversible EGFR inhibitor (i.e., erlotinib or gefitinib). This study ... Li D et al. "BIBW2992, an irreversible EGFR/HER2 inhibitor highlyeffective in preclinical lung cancer ....
... initiation of BPH, either D-3263, finasteride (an inhibitor of the enzyme 5-alpha-reductase) or a combination ... of the two. While finasteride is a known inhibitor of 5-alpha reductase, the enzyme that converts testosterone to DHT, D-3263 is not an inhibitor of this enzyme suggesting that the two agents may ...
... time that the combination of an oral protease inhibitor and an oral nucleoside polymerase inhibitor resulted in significant HCV viral load reduction ... (ITMN-191) R7227 is a potent, macrocyclic inhibitor of HCV NS3/4A protease activity, and has produced ...
... with HCV genotype 1. ITMN-191 is an HCV protease inhibitor being developed in collaboration with Roche. ... 2009. A Phase 1 trial of ITMN-191 and polymerase inhibitor R7128 (INFORM-1 Study) is currently underway. ... hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) ...
... ANA598 as a leading non-nucleoside polymerase inhibitor in development for the treatment of HCV, and we ... of ANA598 with interferon-alpha, the protease inhibitor telaprevir and the nucleoside polymerase inhibitor PSI-6130 are synergistic. These studies also ...
... care Update on next-generation HCV protease inhibitor SCH 900518 presented at EASL annual meeting ... study, known as HCV SPRINT-1 (HCV Serine Protease inhibitor Therapy-1), boceprevir (800 mg TID) was evaluated ... by week 4, therefore patients have the protease inhibitor added at a time when the backbone drug levels ...
... of PCI-32765, an orally available, selective inhibitor of Bruton's tyrosine kinase, or Btk, as a ... lymphoma (NHL). This is the first Btk selective inhibitor to be tested in humans, and is Pharmacyclics' ... Fort Collins, CO About Pharmacyclics' Btk inhibitor Program PCI-32765 is currently targeted ...
... This includes a leading histone deacetylase inhibitor (PCI-24781) for multiple cancers; an inhibitor of Factor VIIa (PCI-27483) targeting pancreatic, ... colon and breast cancers; a first in class inhibitor of Bruton's tyrosine kinase (Btk) (PCI-32765) ...
... for use in HIV therapy is ritonavir, a protease inhibitor that has inherent antiviral activity. SPI-452 was designed to be a potent inhibitor of CYP3A enzymes with no antiviral activity and ... The first IND is for SPI- 256, an HIV protease inhibitor in phase 1 clinical development. The second ...
... (FDA) has granted priority review for Cinryze C1 inhibitor (human) as a treatment for acute attacks of ... subsequent HAE attacks. About Cinryze C1 inhibitor (human) Cinryze is a highly purified, pasteurized and nanofiltered plasma-derived C1 inhibitor product that has been approved by FDA for routine ...
... trials for their lead pyrimidinedione HIV inhibitor IQP-0410. ImQuest anticipates initiating their ... of 2009. IQP-0410 is a novel small molecule inhibitor of HIV which primarily acts as a nonnucleoside reverse transcriptase inhibitor (NNRTI). The compound possesses a second ...
... CX-4945 represents the first potent and selective inhibitor of CK2 with a favorable safety profile and the ... About CX-4945, an oral CK2 protein kinase inhibitor CX-4945 is a first-in-class small molecule ... with the objective of creating a multifunctional inhibitor by targeting a single protein and affecting ...
... to suggest a survival benefit for an aromatase inhibitor versus tamoxifen in the monotherapy setting ... seeing suggested survival benefit with aromatase inhibitor therapy for five years compared with tamoxifen ... both a head-to-head comparison of an aromatase inhibitor with tamoxifen during the first five years ...
... Oncology. Tasigna is a tyrosine kinase inhibitor approved for the treatment of adult Ph+ CML ... is recommended (400 mg once daily). If the strong inhibitor is discontinued, a washout period should be ... to the indicated dose. Tasigna is a competitive inhibitor of CYP3A4, CYP2C8, CYP2C9, CYP2D6, and UGT1A1. ...
... 1-Year Results of TOPS (Tyrosine Kinase inhibitor Optimization and Selectivity) Study (ASH ... Panobinostat (LBH589), a Novel Pan-Deacetylase inhibitor (DACi) Demonstrating Efficacy in Patients with ... is metabolized by the CYP3A4 isoenzyme and is an inhibitor of CYP3A4, CYP2D6 and CYP2C9. Dosage of Gleevec ...
... characterization of its oral proteasome inhibitor known as PR-047. A complete list of the ... Poster II -- The Selective Proteasome inhibitor Carfilzomib is Well Tolerated in ... Characterization of PR-047, An Oral inhibitor of the 20S Proteasome (Abstract #3671) ...
... lead investigational oral hepatitis C protease inhibitor currently in Phase III development. The company ... to be a first-in-class and best-in-class protease inhibitor for treating chronic hepatitis C. The company ... potent next-generation oral hepatitis C protease inhibitor that has future best-in-class potential. The ...
... of PSI-6130, a cytidine nucleoside analog inhibitor of HCV RNA polymerase. A pro-drug is a chemically ... trial. About R7227 (ITMN-191) R7227 is an inhibitor of HCV NS3/4A protease activity, and has ... The hepatology portfolio includes HCV protease inhibitor ITMN-191 (R7227) in Phase 1b, a second-generation ...
... for Non-Nucleoside HCV Polymerase inhibitor Being Presented at AASLD SAN DIEGO, Nov. 1 ... Antiviral Agents that Include HCV Polymerase inhibitor ANA598 have the Potential to Overcome Viral ... synergistic with interferon-alpha, the protease inhibitor telaprevir (VX-950), and the nucleoside ...
... non-nucleoside reverse transcriptase inhibitor (NNRTI) TMC278 (rilpivirine hydrochloride 25 mg) ... with a non-nucleoside reverse transcriptase inhibitor or a protease inhibitor as a preferred regimen for patients initiating ...
Schering-Plough Expands Vicriviroc Phase II Study in Treatment-Naive Patients With HIV
... of the immune system, vicriviroc is an HIV entry inhibitor designed to prevent the virus from infecting ... therapy. Atazanavir is a product in the protease inhibitor (PI) class of HIV medications. Truvada is a ... in the nucleoside(tide) reverse transcriptase inhibitor (NRTI) class. The standard of care for ...... Medicine, Proteolix's selective immunoproteasome inhibitor PR-957 was shown to block disease progression in ... print edition in an article titled: A Selective inhibitor of the Immunoproteasome Subunit LMP7 Blocks ... is the first highly selective, small molecule inhibitor of the immunoproteasome. The proteasome is an ...
... activity as a highly selective and potent inhibitor of the proteasome for treatment of solid tumor ... for carfilzomib as a promising new protease inhibitor in hematologic and solid tumor malignancies. ... including a selective, oral proteasome inhibitor and a selective immunoproteasome inhibitor. For ...
... "We've known that these CYP2D6 inhibitor drugs block the activation of tamoxifen ... far lower levels in the blood stream when CYP2D6 inhibitor drugs are present, and it is the first study to ... that patients used tamoxifen and a CYP2D6 inhibitor concurrently was 340 days. The analysis ...
... Failing Treatment Either with a VEGF Receptor inhibitor or after Treatment with both a VEGF Receptor inhibitor and an mTOR inhibitor NEW YORK, May 29 /PRNewswire-FirstCall/ -- ...
Scientific Data Relating to Cinryze(TM) Presented at 6th Annual C1 Inhibitor Deficiency Workshop
... abstracts relating to Cinryze(TM) (C1 esterase inhibitor [human]) therapy at the 6th Annual C1 inhibitor Deficiency Workshop. Cinryze was approved ... approved, Cinryze would be the first C1 esterase inhibitor available for the acute treatment for this ...Ascenta Therapeutics Announces Multiple Presentations on AT-101 at 2009 ASCO Annual Meeting
... p.m. Min P, et al. Small molecule pan-bcl-2 inhibitor AT-101 induces apoptosis in NSCLC by upregulating ... al. Extended phase I trial of the oral pan-Bcl-2 inhibitor AT-101 by multiple dosing schedules in patients ... AT-101 AT-101 is an orally-active, pan-Bcl-2 inhibitor (including Bcl-2, Bcl-xL, Bcl-w, and Mcl-1 ...... dimesylate) CII with the proton pump inhibitor (PPI) Prilosec OTC(R) 40 mg (20 mg X 2), did not ... the first to evaluate the impact of a proton pump inhibitor on the amphetamine pharmacokinetics of VYVANSE ... drugs; agitated states; taken a monoamine oxidase inhibitor (MAOI) within the last 14 days. Tell the ...
... for Semafore's vascular targeted pan-PI3K/mTOR inhibitor is scheduled as follows: Time: ... SF1126 a vascular targeted PI3K Title: inhibitor administered twice weekly IV in patients with ... only clinical stage vascular targeted pan-PI3K inhibitor that selectively inhibits all PI3K class I ...
... 2992 is an orally-administered, irreversible dual inhibitor of the epidermal growth factor receptor (EGFR) ... with a second-line or third-line reversible EGFR inhibitor (i.e., erlotinib or gefitinib). This study ... Li D et al. "BIBW2992, an irreversible EGFR/HER2 inhibitor highlyeffective in preclinical lung cancer ....
FDA Accepts Arno Therapeutics' IND for AR-12 a PDK1 Inhibitor That Blocks the PI3K/Akt Pathway
... first-in-class, orally available, PDK1 inhibitor that blocks the PI3K/Akt pathway and induces the ... first-in-class, orally available, PDK1 inhibitor that blocks the PI3K/Akt pathway and induces the ... a potential first-in-class, orally available PDK1 inhibitor that blocks the PI3K/Akt pathway and induces the ...Isis and Collaborators Present New Research at the ATVB Annual Conference
... research programs, one on a direct antisense inhibitor of apoC-III, which may provide a promising new ... lower triglycerides, and a second on an antisense inhibitor to Factor XI, which has the potential to create a ... models. "The potential to add an apoC-III inhibitor in the near-term to our cardiovascular pipeline, ...... initiation of BPH, either D-3263, finasteride (an inhibitor of the enzyme 5-alpha-reductase) or a combination ... of the two. While finasteride is a known inhibitor of 5-alpha reductase, the enzyme that converts testosterone to DHT, D-3263 is not an inhibitor of this enzyme suggesting that the two agents may ...
... time that the combination of an oral protease inhibitor and an oral nucleoside polymerase inhibitor resulted in significant HCV viral load reduction ... (ITMN-191) R7227 is a potent, macrocyclic inhibitor of HCV NS3/4A protease activity, and has produced ...
... with HCV genotype 1. ITMN-191 is an HCV protease inhibitor being developed in collaboration with Roche. ... 2009. A Phase 1 trial of ITMN-191 and polymerase inhibitor R7128 (INFORM-1 Study) is currently underway. ... hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) ...
... ANA598 as a leading non-nucleoside polymerase inhibitor in development for the treatment of HCV, and we ... of ANA598 with interferon-alpha, the protease inhibitor telaprevir and the nucleoside polymerase inhibitor PSI-6130 are synergistic. These studies also ...
... care Update on next-generation HCV protease inhibitor SCH 900518 presented at EASL annual meeting ... study, known as HCV SPRINT-1 (HCV Serine Protease inhibitor Therapy-1), boceprevir (800 mg TID) was evaluated ... by week 4, therefore patients have the protease inhibitor added at a time when the backbone drug levels ...
Pharmacyclics announces Global Strategic Alliance with Les Laboratoires Servier
... an orally active, novel, small molecule inhibitor of Pan HDAC enzymes, that is currently in Phase ... its innovative anti-cancer Pan HDAC inhibitor agents. "This alliance with Servier allows ... our unique and differentiated Pan HDAC inhibitor product outside of the United States in rapid ...Cylene to Present Advances in its Oral Inhibitor of CK2 at AACR Annual Meeting
... description of CX-4945, a first-in-class oral inhibitor of protein kinase CK2. CK2 overexpression is ... molecular target. CX-4945 is a potent, selective inhibitor of CK2 and modulates key survival pathways in ... 19, 2009: 8:00 AM CX-4945, a small molecule inhibitor of CK2, inhibits angiogenesis by affecting the ...... of PCI-32765, an orally available, selective inhibitor of Bruton's tyrosine kinase, or Btk, as a ... lymphoma (NHL). This is the first Btk selective inhibitor to be tested in humans, and is Pharmacyclics' ... Fort Collins, CO About Pharmacyclics' Btk inhibitor Program PCI-32765 is currently targeted ...
... This includes a leading histone deacetylase inhibitor (PCI-24781) for multiple cancers; an inhibitor of Factor VIIa (PCI-27483) targeting pancreatic, ... colon and breast cancers; a first in class inhibitor of Bruton's tyrosine kinase (Btk) (PCI-32765) ...
Genaera Presents Preliminary Phase 1b Data for Trodusquemine (MSI-1436)
... (MSI-1436), the first-in-class, highly selective inhibitor of PTP1B and Genaera's lead drug candidate for ... continues to exhibit promise as the only PTP1B inhibitor in development to simultaneously treat both type ... Trodusquemine is the first highly selective inhibitor of protein tyrosine phosphatase 1B (PTP1B), an ...... for use in HIV therapy is ritonavir, a protease inhibitor that has inherent antiviral activity. SPI-452 was designed to be a potent inhibitor of CYP3A enzymes with no antiviral activity and ... The first IND is for SPI- 256, an HIV protease inhibitor in phase 1 clinical development. The second ...
... (FDA) has granted priority review for Cinryze C1 inhibitor (human) as a treatment for acute attacks of ... subsequent HAE attacks. About Cinryze C1 inhibitor (human) Cinryze is a highly purified, pasteurized and nanofiltered plasma-derived C1 inhibitor product that has been approved by FDA for routine ...
ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients
... ANA598 as a leading non-nucleoside polymerase inhibitor in development for the treatment of HCV and we ... been reported for any other non-nucleoside HCV inhibitor in a monotherapy study. Furthermore, the rate of ... agents, ANA598, a non-nucleoside polymerase inhibitor and ANA773, an oral TLR7 agonist prodrug. The ...... trials for their lead pyrimidinedione HIV inhibitor IQP-0410. ImQuest anticipates initiating their ... of 2009. IQP-0410 is a novel small molecule inhibitor of HIV which primarily acts as a nonnucleoside reverse transcriptase inhibitor (NNRTI). The compound possesses a second ...
... CX-4945 represents the first potent and selective inhibitor of CK2 with a favorable safety profile and the ... About CX-4945, an oral CK2 protein kinase inhibitor CX-4945 is a first-in-class small molecule ... with the objective of creating a multifunctional inhibitor by targeting a single protein and affecting ...
... to suggest a survival benefit for an aromatase inhibitor versus tamoxifen in the monotherapy setting ... seeing suggested survival benefit with aromatase inhibitor therapy for five years compared with tamoxifen ... both a head-to-head comparison of an aromatase inhibitor with tamoxifen during the first five years ...
InterMune to Report Top-Line Results of Triple Combination Study of ITMN-191 in January 2009
... 2009 from its Phase 1b clinical trial of protease inhibitor ITMN-191 (R7227) in combination with ... study of ITMN-191 in combination with polymerase inhibitor R7128 (Roche/Pharmasset). INFORM-1 is the first ... portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) ...... Oncology. Tasigna is a tyrosine kinase inhibitor approved for the treatment of adult Ph+ CML ... is recommended (400 mg once daily). If the strong inhibitor is discontinued, a washout period should be ... to the indicated dose. Tasigna is a competitive inhibitor of CYP3A4, CYP2C8, CYP2C9, CYP2D6, and UGT1A1. ...
... 1-Year Results of TOPS (Tyrosine Kinase inhibitor Optimization and Selectivity) Study (ASH ... Panobinostat (LBH589), a Novel Pan-Deacetylase inhibitor (DACi) Demonstrating Efficacy in Patients with ... is metabolized by the CYP3A4 isoenzyme and is an inhibitor of CYP3A4, CYP2D6 and CYP2C9. Dosage of Gleevec ...
... characterization of its oral proteasome inhibitor known as PR-047. A complete list of the ... Poster II -- The Selective Proteasome inhibitor Carfilzomib is Well Tolerated in ... Characterization of PR-047, An Oral inhibitor of the 20S Proteasome (Abstract #3671) ...
Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects
... and Japan); Boceprevir, an oral protease inhibitor for treating hepatitis C with peginterferon and ... SVR; in addition, a next-generation protease inhibitor in Phase II for treating hepatitis C was ... Two projects for Alzheimer's -- a beta secretase inhibitor and a gamma secretase inhibitor; and A ...... lead investigational oral hepatitis C protease inhibitor currently in Phase III development. The company ... to be a first-in-class and best-in-class protease inhibitor for treating chronic hepatitis C. The company ... potent next-generation oral hepatitis C protease inhibitor that has future best-in-class potential. The ...
ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema
... of their family members." About Cinryze C1 inhibitor (human) Cinryze is a highly purified, pasteurized and nanofiltered plasma-derived C1 inhibitor product that has been approved by FDA for routine ... in adolescent and adult patients with HAE. C1 inhibitor therapy has been used acutely for more than 30 ...Tibotec Data Presented at ICAAC and HIV9 Follow Key Regulatory Approvals for Anti-HIV Compounds
... New data on PREZISTA(R) (darunavir), a protease inhibitor from Tibotec, will be presented at the Ninth ... reverse transcriptase inhibitor (NNRTI). The company continues to research ... in combination with a boosted protease inhibitor and other antiretroviral medicinal products, ...... of PSI-6130, a cytidine nucleoside analog inhibitor of HCV RNA polymerase. A pro-drug is a chemically ... trial. About R7227 (ITMN-191) R7227 is an inhibitor of HCV NS3/4A protease activity, and has ... The hepatology portfolio includes HCV protease inhibitor ITMN-191 (R7227) in Phase 1b, a second-generation ...
... for Non-Nucleoside HCV Polymerase inhibitor Being Presented at AASLD SAN DIEGO, Nov. 1 ... Antiviral Agents that Include HCV Polymerase inhibitor ANA598 have the Potential to Overcome Viral ... synergistic with interferon-alpha, the protease inhibitor telaprevir (VX-950), and the nucleoside ...
Other ContentsbunionburnsburnsburnsburnsburnsbunionsbursabursitiscalcificationcalcificationcaffeinecaffeinecaffeineOther TagsScribeScribeScribeScribeFreezerFreezerPorinPaqketoOther Tagsdeposits 2deposits 3plaque 2fighting 2fighting 3fighting 4fighting 5fighting 6usually 2usually 3usually 4usually 5usually 6usually 7usually 8usually 9usually 10simpler 2simpler 3
(Date:11/26/2009)...sharks are some of the Ocean,s most distinctive re...ve this strange head shape, says Michelle McComb ...son is the shark,s vision. ,Perhaps their visual f... says McComb, giving the sharks excellent stereovi...cComb, there were two schools of thought on this t...
(Date:11/26/2009)...their impressive antlers, red deer have been caugh...er,s antlers are much more than decorative. They a...uelling. John Currey, from The University of York,...es of bone for over half a century and has become ...through a long-standing collaboration with Tomas L...
(Date:11/26/2009)...have at last worked out a way of using recordings ... populations. This is the first time sound recordi...nto accurate estimates of bird species, population...ish Ecological Society,s Journal of Applied Ecolo... to a major advance in our ability to monitor whal...
Breaking Biology News(10 mins):Wide heads give hammerheads exceptional stereo view 2Tough yet stiff deer antler is materials scientist's dream 2Ecologists sound out new solution for monitoring cryptic species 2AAHSA Statement on House Ways and Means Committee Hearing 49988 1AAHSA Statement on House Ways and Means Committee Hearing 49988 2Statement of Dr Elena Rios MD MSPH President and CEO National Hispanic Medical Association 49986 1Allscripts to Announce Fiscal Fourth Quarter and Year End Results on July 20 2009 49984 1Allscripts to Announce Fiscal Fourth Quarter and Year End Results on July 20 2009 49984 2Allscripts to Announce Fiscal Fourth Quarter and Year End Results on July 20 2009 49984 3Allscripts to Announce Fiscal Fourth Quarter and Year End Results on July 20 2009 49984 4(Date:11/28/2009)...e/ -- Get ready for advanced visualization to b...when Siemens introduces syngo. via(1) at th...he Radiological Society of North America (RSNA) fr...ooth #825, East Building/Lakeside Center, Hall D) ... imaging software for multimodality reading of cli...
(Date:11/28/2009)...ider change after 30-minute psychosocial intervent...althDay News) -- A program that gets persistent dr... dangerous behavior may lead to significant and lo...he new study included 184 men and women with two o...e randomly assigned to one of two interventions. T...
(Date:11/28/2009)...fect circadian rhythm, , , FRIDAY, ...that an internal body clock that goes on the fritz...isorder in children. , The finding results fro...ldren with bipolar disorder, which can make people...n without the disorder. They linked variations in ...
(Date:11/28/2009)...recognize signs of depression , , SATURD...the holiday season can trigger melancholy as they ...issues or worry about money problems, according to...rcome the seasonal blues, the AGS Foundation for H...t out and socialize or invite family and friends o...
(Date:11/27/2009)...ewswire-FirstCall/ -- GSI Group Inc. (Pink Sheets:...chnology products and semiconductor systems, today... shareholders has been scheduled for Friday, April...ill be announced in due course. As previously ann...from Stephen Bershad, a holder of greater than ten...
Breaking Medicine News(10 mins):Health News:Siemens Boosts Advanced Image Reading Efficiency and Opens New Path Into The Clinical Routine with syngo(R).via 2Health News:Siemens Boosts Advanced Image Reading Efficiency and Opens New Path Into The Clinical Routine with syngo(R).via 3Health News:Siemens Boosts Advanced Image Reading Efficiency and Opens New Path Into The Clinical Routine with syngo(R).via 4Health News:Siemens Boosts Advanced Image Reading Efficiency and Opens New Path Into The Clinical Routine with syngo(R).via 5Health News:Drunk Drivers May Respond to Brief Motivational Interview 2Health News:Bipolar Disorder May Be Tied to Body Clock 2Health News:Seniors May Need Help Overcoming Holiday Blues 2Health News:GSI Group Calls Shareholders Meeting 2[0] Siemens Boosts Advanced Image Reading Efficiency and Opens New Path Into The Clinical Routine with syngo(R).via[0] Drunk Drivers May Respond to Brief Motivational Interview[0] Bipolar Disorder May Be Tied to Body Clock[0] Seniors May Need Help Overcoming Holiday Blues[0] GSI Group Calls Shareholders Meeting
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |